Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2016 | How daratumumab will change the treatment of multiple myeloma

Antonio Palumbo • 3 Jun 2016
EHA 2016
Multiple Myeloma Antibodies Bortezomib Daratumumab Dexamethasone Lenalidomide

Antonio Palumbo, MD from the University of Turin, Turin, Italy discusses the place of daratumumab in the current treatment landscape of multiple myeloma (MM). According to Dr Palumbo, daratumumab will change the treatment paradigm and will be combined to bortezomib and dexamethasone or lenalidomide and dexamethasone.
Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.

More from Antonio Palumbo

10:48
Early treatment and novel therapeutic targets for multiple myeloma
Antonio Palumbo et al. • 11 Apr 2015
1:36
Perspectives on future paths to cure multiple myeloma
Antonio Palumbo • 22 Apr 2016
1:27
Frontline therapy for multiple myeloma
Antonio Palumbo • 30 Apr 2016
1:38
Definitions of smouldering myeloma and when to treat
Antonio Palumbo • 29 Apr 2016

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals